Skip to content

Effect of Unani polyherbal formulation along with tuberculosis treatment(DOTS therapy) in newly diagnosed tuberculosis patients

Efficacy of Unani polyherbal formulation as an adjunct therapy in category-I tuberculosis patients on DOTS therapy - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/073296
Enrollment
70
Registered
2024-09-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A150- Tuberculosis of lung

Interventions

Intervention1: DOTS treatment with Unani polyherbal formulation: Unani polyherbal formulation (Joshanda) consists of following drugs : 1. Banafsha (Viola odorata)- 1gm, 2. Aslasoos (Glycyrrhiza glabra

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who have evidence of active tuberculosis (defined as having symptoms of fever or cough and a sputum smear that showed Acid fast bacilli or a chest X-ray that shows changes compatible with a diagnosis of tuberculosis). 2. Age between 18-60 years. 3. Patients of either sex.

Exclusion criteria

Exclusion criteria: 1. Patients who are hypersensitive to ATTs being administered. 2. Patients already started on ATT for more than 1 week. 3. Patients co-infected with HIV, hepatitis, malignancy, other co-morbid diseases, COPD and uncontrolled DM and hypertension. 4. Pregnant and lactating females. 5. Seriously ill patients.

Design outcomes

Primary

MeasureTime frame
Assessment of : 1. Symptoms 2. Sputum smear, Complete haemogram, CRP, LFT, RFTTimepoint: 1. 0th, 15th, 30th, 45th and 60th days 2. 0th, 30th and 60th days

Secondary

MeasureTime frame
Chest X-rayTimepoint: Before and After the treatment

Countries

India

Contacts

Public ContactMAHERA SAMRIN

National Institute of Unani Medicine

kzarnigar15@gmail.com7483244027

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026